EI
TPTX

EAM Investors’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

EAM Investors’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,103
Closed -$1.72M – 481
2020
Q4 		$1.72M Sell
14,103
-5,271
-27% -$577K 0.28% 164
2020
Q3 		$1.69M Buy
+19,374
New +$1.35M 0.4% 81
2019
Q4 		– Sell
-49,721
Closed -$1.87M – 344
2019
Q3 		$1.87M Buy
+49,721
New +$2.16M 0.49% 71

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

EAM Investors's TPTX Position: Q1 2021 in Review

EAM Investors sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2021, closing a stake of 14,103 shares — an estimated $1.72M sold.

EAM Investors first reported a position in TPTX in Q3 2019 and held it in 3 quarters. The position peaked at $1.87M in Q3 2019. 202 funds tracked by Wall St. Rank hold TPTX as of Q1 2021.

  • EAM Investors reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • EAM Investors sold 14,103 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $1.72M.
  • EAM Investors first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 3 quarters.
  • EAM Investors's Turning Point Therapeutics, Inc. Common Stock position peaked at $1.87M in Q3 2019.
  • 202 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2021.

Based on EAM Investors's 13F filing for Q1 2021, filed 11 May 2021.